Unknown

Dataset Information

0

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension.


ABSTRACT: OBJECTIVE:The efficacy and safety of 1-month atomoxetine and midodrine therapies were compared. Three-month atomoxetine and combination therapies were investigated for additional benefits. METHODS:This prospective open-label randomized trial included 50 patients with symptomatic neurogenic orthostatic hypotension (nOH). The patients received either atomoxetine 18 mg daily or midodrine 5 mg twice daily and were evaluated 1 and 3 months later. Those who still met the criteria for nOH at 1 month received both midodrine and atomoxetine for an additional 2 months, and if not, they continued their initial medication. The primary outcome was an improvement in orthostatic blood pressure (BP) drop (maximum BP change from supine to 3 min after standing) at 1 month. The secondary endpoints were symptom scores, percentage of patients with nOH at 1 and 3 months. RESULTS:Patients with midodrine or atomoxetine treatment showed comparative improvement in the orthostatic BP drop, and overall only 26.2% of the patients had nOH at 1 month, which was similar between the treatment groups. Only atomoxetine resulted in significant symptomatic improvements at 1 month. For those without nOH at 1 month, there was additional symptomatic improvement at 3 months with their initial medication. For those with nOH at 1 month, the combination treatment resulted in no additional improvement. Mild-to-moderate adverse events were reported by 11.6% of the patients. INTERPRETATION:One-month atomoxetine treatment was effective and safe in nOH patients. Atomoxetine improved orthostatic BP changes as much as midodrine and was better in terms of ameliorating nOH symptoms.

SUBMITTER: Byun JI 

PROVIDER: S-EPMC6952305 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension.

Byun Jung-Ick JI   Kim Do-Yong DY   Moon Jangsup J   Shin Hye-Rim HR   Sunwoo Jun-Sang JS   Lee Woo-Jin WJ   Lee Han-Sang HS   Park Kyung-Il KI   Lee Soon-Tae ST   Jung Keun-Hwa KH   Jung Ki-Young KY   Kim Manho M   Lee Sang Kun SK   Chu Kon K  

Annals of clinical and translational neurology 20191219 1


<h4>Objective</h4>The efficacy and safety of 1-month atomoxetine and midodrine therapies were compared. Three-month atomoxetine and combination therapies were investigated for additional benefits.<h4>Methods</h4>This prospective open-label randomized trial included 50 patients with symptomatic neurogenic orthostatic hypotension (nOH). The patients received either atomoxetine 18 mg daily or midodrine 5 mg twice daily and were evaluated 1 and 3 months later. Those who still met the criteria for nO  ...[more]

Similar Datasets

| S-EPMC4231172 | biostudies-literature
| S-EPMC6309809 | biostudies-literature
| S-EPMC10257554 | biostudies-literature
| S-EPMC5506688 | biostudies-literature
| S-EPMC8629777 | biostudies-literature
| S-EPMC4945429 | biostudies-literature
| S-EPMC3797331 | biostudies-literature
| S-EPMC6417751 | biostudies-literature
| S-EPMC5427571 | biostudies-literature
| S-EPMC6601146 | biostudies-literature